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Letter to the Editor
Sylvatic Dengue Viruses Share the Pathogenic Potential
of Urban/Endemic Dengue Viruses
Dengue virus (DENV) exists in both sylvatic and urban/
endemic ecotypes (15), and the potential for emergence of
sylvatic strains has become a focus of research. Recently Mota
and Rico-Hesse (10) attempted to evaluate the pathogenic
potential of viruses belonging to different genetic subgroups of
DENV serotype 2 (DENV-2). Based on the viremia levels and
erythema index profiles of one sylvatic genotype and three
(Asian, American, and Indian) urban/endemic genotypes eval-
uated using the NOD-scid IL2rnull humanized mouse model,
the authors concluded that sylvatic DENV-2 viruses possess a
reduced pathogenic potential compared to strains belonging to
urban/endemic DENV-2 genotypes. However, these conclu-
sions ignore both patterns in their own data and a wealth of
published ex vivo, in vivo, and epidemiological evidence col-
lected over the past 40 years.
First, Mota and Rico-Hesse (10) reported that in their
mouse model, the sylvatic virus produced a peak virus titer,
which is correlated with DENV disease in humans (8, 11, 18),
that was significantly lower than that of the Asian genotype but
higher than that of either the American or Indian genotypes.
Second, the sylvatic virus caused significantly less erythema
than viruses of any of the urban/endemic genotypes. However,
other studies have concluded that the association of erythema
with disease severity is not clear (2). Finally, thrombocytope-
nia, which is more directly pertinent to disease severity (1, 19),
was as severe or more severe in mice infected with sylvatic
DENV than in mice infected with the other DENV-2 geno-
types. In sum, these data suggest that sylvatic DENV may have
a potential to cause dengue disease that is equal to or greater
than those of at least two established urban/endemic geno-
types.
The results of Mota and Rico-Hesse (10) are consistent with
previous ex vivo experiments utilizing monocyte-derived den-
dritic cells (moDCs) as a surrogate model of human infection
that demonstrated no consistent differences in the level of
replication of sylvatic DENV-2 strains from that of urban/
endemic strains, although the Asian genotype achieved higher
titers than all other genotypes (16). Similarly, in vivo experi-
ments utilizing the SCID-Huh-7 xenograft mouse model
yielded no consistent differences in the replication profiles
between sylvatic and endemic strains (16).
The suggestion that sylvatic DENV viruses pose little risk to
human health is also contradicted by several documented cases
of sylvatic DENV-2 infection resulting in clinical illness indis-
tinguishable from classic dengue fever (DF) (4, 9, 12, 14, 17).
Even more compelling is a recent, severe dengue case caused
by a sylvatic strain from southeast Asia, which underscores the
potential of sylvatic strains to cause hemorrhagic manifesta-
tions in humans (3). All of this evidence and most of the
publications cited above were ignored by Mota and Rico-Hesse
(10).
Finally, Mota and Rico-Hesse (10) argue that reemergence
into the urban transmission cycle by sylvatic DENV strains is
unlikely for the following reasons: (i) sylvatic strains have not
caused any outbreaks in West Africa, and (ii) their sylvan
transmission foci are being eliminated due to human environ-
mental disruption. While extensive environmental disruption
has occurred throughout the tropics, there is strong, published
evidence of continuing sylvatic DENV outbreaks as well as
human and primate seroconversions in West Africa (4, 7, 17).
Research sponsored by the Institut Pasteur de Dakar has doc-
umented multiple sylvatic amplification cycles occurring at
roughly 8-year intervals since 1980 in West Africa (5, 6, 13, 14).
The most recent amplification cycle with the isolation of syl-
vatic DENV-2 from mosquito collections and human infections
was documented in 2008 (A. Sall, Institut Pasteur de Dakar Sene-
gal, personal communication). The recent isolation of DENV-2
from a human patient infected in peninsular Malaysia and its
close relationship to a sylvatic strain isolated nearby from a sen-
tinel monkey in 1970 also indicate the undetected maintenance of
sylvatic DENV in a zoonotic cycle in southeast Asia for nearly 4
decades (3). Thus, the assertion of Mota and Rico-Hesse (10) that
sylvatic dengue virus foci have been eliminated is baseless.
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